Evidence map›Paper›PMID 37153695›Full record

ArticleIn silico pharmacology2023

Potential peptidyl arginine deiminase type 4 inhibitors from

Debashis Roy Chowdhury, Rajat Ghosh, Sudhan Debnath, Samhita Bhaumik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In silico pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Debashis Roy ChowdhuryDepartment of Chemistry, Netaji Subhash Mahavidyalaya, Udaipur, 799114 India.
Rajat GhoshDepartment of Pharmacy, Tripura University, Suryamani Nagar, Agartala, Tripura 799022 India.
Sudhan DebnathDepartment of Chemistry, Netaji Subhash Mahavidyalaya, Udaipur, 799114 India.
Samhita BhaumikDepartment of Chemistry, Womens College, Agartala, Tripura 799001 India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The World Health Organization estimates that more than 23 million individuals worldwide suffer from rheumatoid arthritis (RA), a chronic systemic autoimmune disease and experts predict that the number of RA patients may double by 2030. A substantial portion of RA patients do not respond effectively to the treatment that are already available therefore there is an urgent need of innovative new drugs. Over the past several years, Peptidyl Arginine Deiminase Type 4 (PAD4) receptors have become potential therapeutic targets for the treatment of RA. The main objective of the present study is to identify potential PAD4 inhibitors from edible fruits Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-023-00147-3.

Indexed as

ADMEEdible fruitsM. citrifoliaMolecular dockingMolecular dynamicsPAD4 receptorRheumatoid arthritis

Identifiers

PMID37153695
PMCPMC10154455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.